Reviewing the Compounding Risks for Tuberculosis Drug-Induced Liver Injury in a Patient with Transfusion Dependent Thalassaemia-Reference-Cited by-同舟云学术

Reviewing the Compounding Risks for Tuberculosis Drug-Induced Liver Injury in a Patient with Transfusion Dependent Thalassaemia

Published:2023-07-07 Issue:4 Volume:19 Page:365-367
ISSN:1675-8544
Container-title:JULY 2023
language:en
Short-container-title:MJMHS

Author:

Rofii Nursafinas,Daut Ummi Nadira,Lau Su Yin

Abstract

A patient presents with jaundice three weeks into commencement of anti-tuberculosis therapy (ATT). Tuberculosis drug-induced liver injury (TB-DILI) is a main concern in patients commencing ATT. Studies have reported various risk factors associated with TB-DILI, urging vigilance in monitoring liver enzymes in these patients. We aim to review the causes of jaundice in a patient with transfusion dependent thalassaemia commenced on ATT and highlight the risk factors associated with TB-DILI.

Publisher

Universiti Putra Malaysia

Subject

General Medicine

Reference5 articles.

1. 1. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011 Jun;89(6):806-15. doi: 10.1038/clpt.2011.58.

2. 2. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–52. doi: 10.1164/rccm.200510-1666ST.

3. 3. Capelle P, Dhumeaux D, Mora M, Feldmann G, Berthelot P. Effect of rifampicin on liver function in man. Gut. 1972;13(5):366–71. doi: 10.1136/gut.13.5.366.

4. 4. Patterson B, Abbara A, Collin S, Henderson M, Shehata M, Gorgui-Naguib H, et al. Predicting drug-induced liver injury from anti-tuberculous medications by early monitoring of liver tests. Journal of Infection. 2021;82(2):240–4. doi: 10.1016/j.jinf.2020.09.038

5. 5. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Müllhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009 Oct;51(4):655–66. doi: 10.1016/j.jhep.2009.05.016